ESPERION THERAPEUTICS INC

ESPR NASDAQ

BuySellMarketMaker

In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease. Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. (tipranks.com) Analyst...

AlTorress

This indicator may be signaling that ESPR's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. Tickeron's A.I.dvisor backtested 94 similar cases where ESPR's Momentum Indicator exceeded 0, and 81 of them led to a successful outcome. Odds of Success: 86%....

shishoo

Long term wave count with potential entry and exit zones

AlTorress

This indicator may be signaling that ESPR's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. Tickeron A.I.dvisor backtested 96 similar cases where ESPR's Momentum Indicator exceeded 0, and 84 of them led to a successful outcome. Odds of Success: 88%....

Will Wong

Sweet 3 of 3 next. Target $110 which is almost 4 times the current price.

Bullishcharts

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul...

RocketTickers

ESPR: Esperion Therapeutics, Inc. 2020-02-26 17:30:10 Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

JenRz

I just started playing with FDA approvals using my pendulum. I don't see anything good coming out of this news event other than a bounce to sell into. Symmetry support is $57.15 held once. Will it twice?? If it doesn't hold this 786 fib (53.99), the door is open to $40.

RocketTickers

ESPR: Esperion Therapeutics, Inc. 2020-02-21 16:38:10 Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

JenRz

BE CAREFUL!! I'm getting bad vibes on the news for tomorrow in this one. This is based on my dowsing work and it suggests a drop of 38%. That would rock it down to about $42.50 FYI I don't know anything about the fundamentals or background on this pending approval, and I really don't know anything about the company, nor do I care. I'm not super confident yet in...

Will Wong

retrace for an entry position at base of handle.

jaxdog

I took this position yesterday when it broke back above the handle line on this near textbook Cup with Handle pattern (it's a little deep, but I still like it)... My stop is $46, Entry $52.55. My first target is the last high of $60 then on to it's all time high around $80... Ideas, Not investing / trading advice.

Mkhalid206

Not Financial Advice: Biggest thing to watch is the small squeeze taking place that should send it further down. Time will tell if they announce any breakthroughs.

RocketTickers

ESPR: Esperion 2018-08-27 07:00:00 Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study

Brotank77

ESPR is oversold according To RSi. Looks like it has gapped down to a support area. Billion Dollar company- dont think it will be going broke anytime soon. More than likely they have other products going on. And supposedly the news isnt as bad as it seems. there is a law suit pending which could drive the stock down more. So keep on your watch list.

dzynr64

Stock had buy signals generated in 2nd half of December: Stochastics Momentum Index on 19DEC17 Stochastic RSI on 22DEC17 volume-price on 27DEC17 Waiting for price to hit my lower trend line, maybe next week

ElliotWaveTrades

ESPR rallied 85% from its last consolidation to its near term high at $57.38. Prices have since been in consolidation mode in the form of a expanded FLAT. The consolidation appears to be completed. A successful break to the upside could bring prices to a range between $82.24 (Fib Exp 1.5x) to $85.36 (Fib Exp 1.618x) Break of Critical Support could imply any of...

Topclasstrader

TIME to BUY On support. We believe this stock will spike in short time. BUY and HOLD MPP for Profit